Fagron France a republié ceci
Fagron has published today its quarterly results for the period ending 31 March 2025. Record first-quarter revenue of €239 million, reflecting 14% topline growth Key Highlights: · Revenue maintained its strong growth momentum, increasing 14.1% on reported basis to €238.7 million (15.2% at CER), with all regions and segments contributing · Organic growth at CER of 12.6% reflects strong performance in North America, and an exceptional performance in Latin America · Global operational excellence initiatives on track and yielding efficiencies · CareFirst acquisition closed in addition to EuroOTC and Guinama. Integration of all transactions progressing as planned and we remain committed to disciplined acquisition strategy · In March 2025, FDA confirmed corrective actions at the Wichita facility adequately address requirements, pending site visit · FY 2025 guidance reaffirmed: mid- to high-single digit organic sales growth at CER and slight improvement in profitability You can find the Q1 Presentation at: https://lnkd.in/emy3FhqT